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Abstract
Introduction Dermatology is usually thought of as an outpatient
specialty with low mortality, however some skin conditions
require intensive care. These conditions are relatively rare and
hence are best studied using clinical databases or disease
registries. We interrogated a large, high-quality clinical database
from a national audit of adult intensive care units (ICUs), with the
aim of identifying and characterising patients with
dermatological conditions requiring admission to ICU.
Methods Data were extracted for 476,224 admissions to 178
ICUs in England, Wales and Northern Ireland participating in the
Case Mix Programme over the time period December 1995 to
September 2006. We identified admissions with dermatological
conditions from the primary and secondary reasons for
admission to ICU.
Results A total of 2,245 dermatological admissions were
identified. Conditions included infectious conditions (e.g.
cutaneous cellulitis, necrotising fasciitis), dermatological
malignancies, and acute skin failure (e.g. toxic epidermal
necrolysis, Stevens–Johnson syndrome and autoimmune
blistering diseases). These represent 0.47% of all ICU
admissions, or approximately 2.1 dermatological admissions per
ICU per year. Overall mortality was 28.1% in the ICU and 40.0%
in hospital. Length of stay in intensive care was longest for those
with acute skin failure (median 4.7 days for ICU survivors and
5.1 days for ICU non-survivors).
Conclusion We have identified patients who not only require
intensive care, but also dermatological care. Such patients have
high mortality rates and long ICU stays within the spectrum of
the UK ICU population, similar to other acute medical
conditions. This highlights the importance of skin failure as a
distinct entity comparable to other organ system failures.
Introduction
Dermatology is usually thought of as an outpatient specialty
with low mortality. However, some skin conditions can be very
severe and the condition itself, or associated complications of
the condition or treatment, may cause the patient to require
intensive care. There is little literature dealing specifically with
intensive care dermatology [1,2]. Green et al. described the
skin problems that may arise in a critically ill patient [1]. Dunnill
et al. reported a case series of 27 dermatology patients admit-
ted to a 30-bedded intensive care department at St Thomas's
Hospital over a 14-month period [2].
Conditions that may require intensive care management
include toxic epidermal necrolysis (TEN), Stevens–Johnson
syndrome (SJS), necrotising fasciitis and exfoliative dermatitis.
Patients with large areas of skin involvement have problems
with fluid and electrolyte balance and with temperature control
as a result of large daily percutaneous fluid losses [2]. In criti-
cally ill patients, hypoalbuminaemia is typically caused by the
systemic inflammatory response syndrome and redistribution.
However, in patients with extensive skin loss, hypoalbuminae-
mia also occurs as a result of cutaneous losses, hypercata-
bolic state and decreased synthesis [2]. Patients withCritical Care    Vol 12 Suppl 1    George et al.
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impaired barrier function are also vulnerable to infection. In
1991, Irvine defined the concept of skin failure and proposed
that it was a real entity comparable to any other major organ
system dysfunction [3]. However, the concept of skin failure is
not well known [4], and skin conditions that may require inten-
sive care are relatively rare. For example, the incidence of TEN
is reported to be between 0.4 and 1.3 cases per million per-
son years and that of SJS between 1–7 cases per million per-
son years (which equate to approximately 50 and 240 cases
per year, respectively, in the UK) [5,6]. The incidence of necr-
otising fasciitis is estimated at 500 new cases per year in the
UK [7]. This makes it difficult for individual clinicians to gain
experience of managing such cases. Conditions with such a
low incidence are best studied using large high quality clinical
databases arising from multicentre audits or disease registries
[8-10]. The collective experience of managing these rare
cases can then be collated.
Our aim was to describe the frequency, physiological parame-
ters, length of stay, and mortality of patients with dermatologi-
cal conditions admitted to UK intensive care units (ICUs)
participating in a national audit of intensive care over a 10-year
period.
Materials and methods
The Case Mix Programme Database
The Case Mix Programme (CMP) is the national, comparative
audit of adult, general critical care units (ICUs and combined
intensive care and high dependency units) in England, Wales
and Northern Ireland. Data are extracted by trained data col-
lectors and undergo extensive local and central validation prior
to inclusion in the CMP Database [11]. Validated data for all
admissions to units participating in the CMP between Decem-
ber 1995 and September 2006 were extracted from the CMP
Database.
The CMP has received approval from the Patient Information
Advisory Group (PIAG), under Section 60 of the Health and
Social Care Act 2001, for the collection and use of patient
identifiable information without individual patient consent
(approval no. PIAG 2-10(f)/2005).
Selection of cases
In the CMP, reasons for admission to the ICU are recorded
using a hierarchical coding method, the Intensive Care
National Audit & Research Centre (ICNARC) coding method
[12]. Cases were selected if the primary or secondary reason
for their admission to ICU was recorded as any of the following
conditions, coded within the dermatological system of the
ICNARC coding method:
￿ necrotising fasciitis;
￿ cutaneous cellulitis;
￿ orbital cellulitis;
￿ cutaneous melanoma;
￿ basal cell carcinoma;
￿ toxic epidermal necrolysis;
￿ Stevens–Johnson syndrome;
￿ erythema multiforme;
￿ exfoliative dermatitis;
￿ pemphigus vulgaris;
￿ psoriasis and pustular psoriasis;
￿ scleroderma.
If both the primary and secondary reasons for admission were
dermatological, then the patient was categorised according to
the primary reason for admission. In addition, patients were
identified if their primary or secondary reason for admission
was partially coded within the dermatological system of the
hierarchical coding method. Partial codes are used when a
specific condition cannot be identified within the coding
method. Partially-coded reasons were reclassified, where pos-
sible, using the process tier of the coding method (e.g. infec-
tion or malignancy) and the free text field.
Analyses
An analysis plan was agreed a priori. For each of the individual
conditions listed above, we summarised the number of admis-
sions and the numbers of these dying in the admitting ICU,
transferred to another ICU, and dying before ultimate dis-
charge from an acute hospital.
The following three groups of conditions (as classified in Table
1) were analysed separately and in more detail:
1. Infective conditions;
2. Dermatological malignancies;
3. Conditions causing acute skin failure.
For these three subgroups, the following measures of case
mix, activity and outcome were summarised.
Case mix
The case mix of admissions was described by the age, sex,
surgical status, severe conditions in the past medical history,
the Acute Physiology And Chronic Health Evaluation
(APACHE) II score and predicted mortality [13], and the ICN-Available online http://ccforum.com/content/12/S1/S1
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Table 1
Dermatological conditions in the Case Mix Programme Database
Condition ICU admissions, n (%*) ICU deaths, n (%) ICU transfers, n (%) Ultimate hospital deaths, n (%)
Infective conditions:
Necrotising fasciitis 1,133 (0.24) 336 (29.7) 56 (4.9) 438 (41.6)
Cutaneous cellulitis 658 (0.14) 193 (29.3) 14 (2.1) 274 (42.6)
Orbital cellulitis 48 (0.01) 8 (16.7) 1 (2.1) 12 (26.7)
Wound infection† 28 (0.01) 2 (7.1) 0 (0.0) 10 (35.7)
Infected ulcer† 27 (0.01) 10 (37.0) 0 (0.0) 17 (65.4)
Abscess† 23 (< 0.01) 2 (8.7) 1 (4.3) 4 (18.2)
Gangrene† 6 (< 0.01) 1 (16.7) 0 (0.0) 1 (16.7)
Infected eczema† 3 (< 0.01) 1 (33.3) 0 (0.0) 1 (33.3)
Dermatological malignancies:
Cutaneous melanoma 80 (0.02) 6 (7.5) 0 (0.0) 13 (16.9)
Basal cell carcinoma 96 (0.02) 6 (6.3) 0 (0.0) 11 (12.0)
Squamous cell carcinoma† 15 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Acute skin failure:
Toxic epidermal necrolysis 86 (0.02) 32 (37.2) 5 (5.8) 43 (50.6)
Stevens–Johnson syndrome 46 (0.01) 14 (30.4) 5 (10.9) 19 (46.3)
Erythema multiforme 19 (< 0.01) 3 (15.8) 2 (10.5) 6 (31.6)
Psoriasis and pustular psoriasis 19 (< 0.01) 8 (42.1) 0 (0.0) 8 (42.1)
Exfoliative dermatitis 16 (< 0.01) 7 (43.8) 0 (0.0) 7 (43.8)
Pemphigus vulgaris 9 (< 0.01) 4 (44.4) 0 (0.0) 4 (44.4)
Cutaneous T cell lymphoma† 2 (< 0.01) 1 (50.0) 0 (0.0) 2 (100.0)
Staphylococcal scalded skin syndrome† 1 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Epidermolysis bullosa† 1 (< 0.01) 1 (100.0) 0 (0.0) 1 (100.0)
Other:
Scleroderma 36 (0.01) 15 (41.7) 1 (2.8) 19 (54.3)
Rash due to systemic infection† 18 (< 0.01) 3 (16.7) 1 (5.6) 5 (38.5)
Pressure sores† 10 (< 0.01) 2 (20.0) 0 (0.0) 3 (33.3)
Allergic reaction† 7 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Allergy testing† 5 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Complication following skin surgery for non 
malignant condition†
4 (< 0.01) 1 (25.0) 0 (0.0) 1 (25.0)
Dermatomyositis† 2 (< 0.01) 1 (50.0) 0 (0.0) 2 (100.0)
Pyoderma gangrenosum† 2 (< 0.01) 2 (100.0) 0 (0.0) 2 (100.0)
Weber-Christian disease† 1 (< 0.01) 0 (0.0) 0 (0.0) 1 (100.0)
Behçet's syndrome† 1 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Wegener's granulomatosis† 1 (< 0.01) 1 (100.0) 0 (0.0) 1 (100.0)
Hypereosinophilia† 1 (< 0.01) 1 (100.0) 0 (0.0) 1 (100.0)
Radiation necrosis† 1 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Axillary hyperhidrosis (thoracic 
sympathectomy)†
1 (< 0.01) 0 (0.0) 0 (0.0) 0 (0.0)
Total 2,406 (0.51) 661 (27.5) 86 (3.6) 906 (39.6)
*Percentage of all admissions in the Case Mix Programme Database. †Identified from partial code and text field. ICU, intensive care unit.Critical Care    Vol 12 Suppl 1    George et al.
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ARC physiology score and predicted mortality [14]. In addi-
tion, for admissions with TEN and related conditions (SJS and
erythema multiforme), the disease-specific SCORTEN severity
scoring system was also used. The SCORTEN comprises a
score for seven factors relating to mortality: age greater than
40 years; heart rate greater than 120 min-1; cancer; involved
body area greater than 10%; serum urea greater than 10
mmol.l-1; serum bicarbonate less than 20 mmol.l-1; and serum
glucose greater than 14 mmol.l-1 [15]. The APACHE II, ICN-
ARC and SCORTEN models were calculated using computer
algorithms based on raw data recorded from the first 24 h in
ICU.
The most frequently occurring non-dermatological reasons for
admission recorded in the database were also reported for all
patients with dermatological conditions.
Outcome
Outcome was described by the mortality in the original admit-
ting ICU and at ultimate discharge from an acute hospital. For
admissions with TEN and related conditions, hospital mortality
was also reported by SCORTEN. The ability of SCORTEN to
discriminate between hospital survivors and non-survivors was
evaluated by the area under the receiver operating character-
istic (ROC) curve [16] and compared with the discrimination
of the APACHE II score and the ICNARC risk prediction
model.
The ROC curve is a plot of the sensitivity against the specifi-
city of the score for predicting death at each different value.
The area under the curve, also called the concordance or c-
index, is equivalent to the probability that a randomly selected
non-survivor will have a higher score than a randomly selected
survivor.
Activity
Activity was described by the number of patients transferred
to another ICU, the number transferred for more specialised
care, the length of stay in ICU by ICU discharge status (dis-
charged, transferred or died), and the total length of stay in an
acute hospital by ultimate hospital survival status.
Results
Out of 476,224 admissions to 178 adult general ICUs from 1
December 1995 to 30 September 2006, 2,245 were cases in
which a dermatological condition was fully specified as the pri-
mary or secondary reason for admission. A further 213 partially
coded dermatological reasons were identified. Of these, three
could be given a full code within the coding method, 158 were
categorised based on the free text field and the remaining 52
had insufficient detail recorded and were excluded from the
analyses. The resulting 2,406 dermatological admissions
(Table 1) represented 0.51% of all admissions in the data-
base, or approximately two dermatological admissions per unit
per year.
Overall, 661 patients (27.5%) with a dermatological condition
died in intensive care with a total of 906 patients (39.6%)
dying before ultimate discharge from an acute hospital. There
were 86 (3.6%) transfers of patients to another ICU.
The most frequent dermatological reasons for admission to
intensive care were infective conditions. There were 1,133
cases of necrotising fasciitis and 658 cases of cutaneous cel-
lulitis, which together made up three quarters of all dermato-
logical admissions to intensive care.
Excluding conditions representing fewer than 20 admissions,
mortality was lowest for patients with cutaneous malignancies,
with 11 (12.0%) hospital deaths amongst patients with basal
cell carcinomas and highest for those with scleroderma with
19 (54.3%) hospital deaths.
Patients with dermatological malignancies were older than
those with infective conditions or acute skin failure (mean age
65 years versus 58 and 52 years, respectively), and there was
a higher percentage of male patients in this group (59% ver-
sus 52% and 45%) (Table 2).
Patients with infective conditions were mostly medical admis-
sions (52.8%) or were admitted following emergency surgery
(38.3%). By comparison, the vast majority of those with der-
matological malignancies were admitted following elective
surgery (72.3%) and most of those with acute skin failure were
non-surgical admissions (85.4%) (Table 2).
Disease severity scores, APACHE II and the ICNARC physiol-
ogy score, were highest in those with infective conditions and
lowest in those with cutaneous malignancies.
Length of intensive care stay was longest for those with acute
skin failure (median 4.7 days for both ICU survivors and non-
survivors). Length of intensive care stay and total hospital stay
was shortest for those with dermatological malignancies.
The most commonly recorded non-dermatological reasons for
admission among these patients were for septic shock/septi-
caemia (n = 573, 23.8%), acute renal failure (n = 168, 7.0%)
and pneumonia (n = 95, 4.0%) (Table 3).
For admissions with TEN, SJS and erythema multiforme (n =
145), mortality increased steeply with SCORTEN (Figure 1),
rising from around 20% for scores of 0–2 to over 70% for
scores of 4 or more. The area under the ROC curve for
SCORTEN was 0.762 (95% confidence interval 0.685–
0.838) (Figure 2). This compared with values of 0.737
(0.655–0.819) for the APACHE II score (in 137 eligible
patients), and 0.795 (0.722–0.867) for the ICNARC model,
suggesting that the ICNARC model was best for discriminat-
ing between survivors and non-survivors in this patient group.
However, with relatively small numbers, none of the differAvailable online http://ccforum.com/content/12/S1/S1
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Table 2
Case mix, outcome and activity for major subgroups of dermatological admissions
Infective conditions Dermatological malignancies Acute skin failure
Admissions, n (% of all admissions) 1,926 (0.40) 191 (0.04) 199 (0.04)
Age, mean (SD) 57.6 (16.5) 65.1 (15.0) 51.7 (20.8)
Male, n (%) 1,009 (52.4) 112 (58.6) 90 (45.2)
Surgical status, n (%):
Non-surgical 1,016 (52.8) 38 (19.9) 170 (85.4)
Elective 172 (8.9) 138 (72.3) 16 (8.0)
Emergency 737 (38.3) 15 (7.9) 13 (6.5)
Past medical history*, n (%):
Steroid treatment 65 (3.4) 3 (1.6) 12 (6.1)
Chemotherapy 43 (2.3) 8 (4.2) 13 (6.6)
Metastatic disease 17 (0.9) 25 (13.2) 0 (0.0)
Chronic renal replacement therapy 37 (1.9) 1 (0.5) 5 (2.5)
Severe respiratory disease 32 (1.7) 1 (0.5) 3 (1.5)
Very severe cardiovascular disease 26 (1.4) 3 (1.6) 3 (1.5)
Radiotherapy 15 (0.8) 11 (5.8) 1 (0.5)
Lymphoma 19 (1.0) 1 (0.5) 6 (3.0)
Acute myelogenous/lymphocytic leukaemia or multiply myeloma 11 (0.6) 0 (0.0) 3 (1.5)
Portal hypertension 12 (0.6) 0 (0.0) 1 (0.5)
Biopsy proven cirrhosis 12 (0.6) 0 (0.0) 0 (0.0)
Chronic myelogenous/lymphocytic leukaemia 8 (0.4) 1 (0.5) 1 (0.5)
Home ventilation 8 (0.4) 1 (0.5) 0 (0.0)
Congenital immunohumoral or cellular immune deficiency state 5 (0.3) 0 (0.0) 1 (0.5)
Hepatic encephalopathy 5 (0.3) 0 (0.0) 0 (0.0)
AIDS 2 (0.1) 0 (0.0) 0 (0.0)
APACHE II score, mean (SD) 19.1 (7.5) 14.5 (5.3) 18.1 (7.0)
ICNARC model:
Physiology score, mean (SD) 22.7 (10.4) 12.1 (6.7) 21.2 (10.6)
Predicted mortality, median (IQR) 37.6 (16.7–64.5) 10.1 (6.2–19.2) 32.7 (12.3–62.7)
ICU length of stay (days), median (IQR):
ICU survivor 4.1 (1.7–10.0) 1.0 (0.8–2.0) 4.7 (1.9–14.8)
ICU non-survivor 1.9 (0.7–5.8) 1.0 (0.3–4.0) 4.7 (2.0–10.0)Critical Care    Vol 12 Suppl 1    George et al.
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Discussion
This report provides information about the range of dermato-
logical conditions requiring intensive care in England over an
11-year period (1995–2006). Of 476,224 admissions to 178
ICUs in England, Wales and Northern Ireland, 2,406 dermato-
logical admissions were identified. While rare, these condi-
tions are important as they have a high mortality and often
require long intensive care and hospital stays. Overall, 28% of
patients died in intensive care, with a total of 40% dying in
hospital. Patients with acute skin failure had the highest mor-
tality with 35% dying in intensive care and a total of 47% dying
in hospital. By comparison, of the overall general adult inten-
sive care population, 20% die in the ICU and 31% die in hos-
pital [11]. While the population of patients admitted to
intensive care is very heterogeneous, comparisons with the
average for all intensive care admissions allow us to place the
dermatological admissions within the spectrum of all ICU
admissions. The hospital mortality of patients admitted to ICU
with acute skin failure is comparable to that of other acute
medical conditions, such as pancreatitis (42%) [17] and pneu-
monia (49%) [18].
As well as having higher mortality, dermatology patients with
infective conditions and acute skin failure also have longer
Transfer to another ICU 4.0 (0.9–9.6) - 3.5 (0.7–11.6)
Total acute hospital length of stay (days), median (IQR):
Hospital survivor 39 (22–66) 17 (8–28) 34 (16–75)
Hospital non-survivor 9 (3–29) 6 (3–22) 15 (7–31)
ICU bed days (% of total bed days) 13,808 (0.60) 391 (0.02) 1,923 (0.08)
Transfer to another ICU, n (%) 72 (3.7) 0 (0.0) 12 (6.0)
ICU mortality, n (%) 553 (28.7) 12 (6.3) 70 (35.2)
Ultimate hospital mortality, n (%) 757 (41.5) 24 (13.0) 90 (46.6)
Values are n (%), mean (SD) or median (IQR), as indicated. *Percentage of admissions with evidence to assess past medical history. APACHE, Acute Physiology And 
Chronic Health Evaluation; ICNARC, Intensive Care National Audit & Research Centre; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
Table 2 (Continued)
Case mix, outcome and activity for major subgroups of dermatological admissions
Table 3
Top 10 most common non-dermatological reasons for admission for patients with both dermatological and non-dermatological 
reasons recorded
Reason Associated non-dermatological reason for admission n (%)
1 Septic shock/septicaemia 573 (23.8)
2 Acute renal failure 168 (7.0)
3 Pneumonia 95 (4.0)
4 Chronic obstructive pulmonary disease (COPD) 36 (1.5)
5 Non-cardiogenic pulmonary oedema 31 (1.3)
6 Diabetes mellitus 27 (1.1)
7 Supra-ventricular tachycardia, atrial fibrillation or flutter 26 (1.1)
8(=) Hypovolaemic shock 25 (1.1)
8(=) Morbid obesity 25 (1.1)
10 Chronic renal failure 22 (0.9)Available online http://ccforum.com/content/12/S1/S1
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intensive care and hospital stays than average for the general
adult intensive care population. The median length of stay in
intensive care for all adult patients is 1.7 days for survivors and
2.0 days for non-survivors, whereas for dermatology patients,
survivors with infective conditions and acute skin failure had
median ICU stays of between 4 and 5 days. In the present
study, ICU deaths in the acute skin failure group occurred
particularly late, with a median ICU stay of 5 days for non-sur-
vivors. The median total hospital stay for patients admitted to
ICUs is 16 days for survivors and 9 days for non-survivors [11].
Our results on hospital length of stay are consistent with two
previous retrospective cohort studies of patients with necrotis-
ing fasciitis, which reported mean hospital stays of around 31
days for survivors and 12 days for non-survivors [19,20]. One
of these studies also reported the overall mean ICU stay as 21
days [20].
ences in ROC curves were statistically significant (SCORTEN versus 
APACHE II, Chi-squared = 0.14, p = 0.73; SCORTEN versus ICN-
ARC model, Chi-squared = 1.08, p = 0.30; ICNARC model versus 
APACHE II, Chi-squared = 1.52, p = 0.22).
Compared with the average for the general adult intensive
care population, APACHE II scores were higher for dermatol-
ogy patients with infective conditions and acute skin failure
(mean scores 19.2 and 18.0, respectively), but lower for der-
matological malignancies (mean score 14.5). These reflect
typical scores for conditions that are predominantly emer-
gency and elective, respectively. They compare with mean
APACHE II scores of 16.5 for all UK intensive care patients
[11] and 19.2 for a previous cohort of 166 patients with necr-
otising fasciitis [19].
The most common dermatological reason for admission to
intensive care (1133 cases) was necrotising fasciitis. Over a
10-year period this corresponds to an overall treated inci-
dence of approximately 280 patients per year in the UK. As the
total UK incidence is estimated at 500 new cases per year [7],
a significant proportion of these cases must be managed
either in more specialised units, or more likely in high depend-
ency units or on the general ward. Mortality in previously
reported case series of patients with necrotising soft tissue
infections varies from 17% to 33% [19-22]. Our patients with
necrotising fasciitis had an overall mortality of 41.6%. This
high mortality is most likely to be due to selection of only the
most severe cases for treatment in an ICU due to the limited
critical care resources in the UK.
Our study included 145 patients who had a diagnosis of TEN
and related conditions (SJS and erythema multiforme). The
data available in the CMP Database allowed us to produce
ROC curves for SCORTEN, the APACHE II score and the
ICNARC model for these cases. SCORTEN was developed
using a sample of 165 patients and validated on a further 75
patients from the same dermatology ICU [15]. The area under
the ROC curve in the validation sample was 0.82 (95% confi-
dence interval 0.74 to 0.90), which indicates good discrimina-
tory power. Further work using a large proportion of the
patients from the original study found that SCORTEN calcu-
lated on any of the first 5 days of admission produced ROC
values of over 0.8 [23]. The area under the ROC curve for
SCORTEN in our study was 0.763, which was better than the
APACHE II score (0.737) but not as good as the ICNARC
model (0.795), although these differences were not statisti-
cally significant. SCORTEN is a simple model, which is quick
and easy to use at the bedside. By comparison, APACHE II
and the ICNARC model are more complex and are designed
to give estimates of the risk of hospital mortality across all
admissions to intensive care. The comparable performance of
the simple SCORTEN model to these more complex models
was therefore impressive.
Only a small number of patients had exfoliative dermatitis,
pemphigus vulgaris, psoriasis and scleroderma, however all of
these conditions had a high mortality. Even smaller numbers
were identified with dermatomyositis, cutaneous T cell lym-
phoma, staphylococcal scalded skin syndrome and epidermo-
lysis bullosa. The rarity of these conditions makes it difficult to
gain experience of managing such cases.
The admission to ICU of patients with comparatively low risk
conditions, such as basal cell carcinoma, may seem surprising.
However, reviewing the free text field of the database for these
cases, where used, indicated that these were likely to be
admissions following complex surgery, in particular operations
involving facial reconstruction. This would explain the relatively
low but not insignificant mortality of 12% among this group.
Our study shows the most common non-dermatological rea-
sons for admission in patients with both dermatological and
non-dermatological reasons recorded were sepsis, acute
renal failure and pneumonia. Unsurprisingly, these represent
common and direct complications of severe skin disorders.
Figure 1
Ultimate hospital mortality by SCORTEN for admissions with toxic epi- dermal necrolysis and related conditions (n = 145) Ultimate hospital mortality by SCORTEN for admissions with toxic epi-
dermal necrolysis and related conditions (n = 145).Critical Care    Vol 12 Suppl 1    George et al.
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They suggest that in some cases the skin condition alone does
not precipitate admission to ICU, but rather the associated
complications. In terms of pre-existing conditions, only the
most severe illnesses in a patient's past medical history are
routinely recorded in the CMP Database. A review of necrotis-
ing fasciitis found that pre-existing conditions included diabe-
tes mellitus (incidence 21–64%), peripheral vascular disease
(15–80%), intravenous drug abuse (8–77%), obesity (18–
46%), chronic alcoholism (12–31%) and malnutrition (18–
40%) [24]. More recent studies have found that the most fre-
quent comorbidities were diabetes (19–37%) [19-21], obes-
ity (17–31%) [20,21], hypertension (35%) [20] and
intravenous drug abuse (30%) [19]. The low rates of condi-
tions such as diabetes and obesity in our results reflect the
fact that these conditions are only recorded in the CMP Data-
base if they are considered to have had a significant influence
on the decision to admit the patient to intensive care.
The dermatological admissions identified therefore represent
a combination of those admitted for their primary dermatolog-
ical condition, such as those with acute skin failure, a direct
complication of that condition, such as septic shock or renal
failure, or as a result of their treatment, such as those admitted
for monitoring following major surgery or following an acute
complication during minor surgery. It is in the first of these
three groups where the involvement of dermatologists may be
of particular benefit in terms of diagnostic advice and knowl-
edge of therapeutic options.
The high mortality and long duration of ICU stay of patients
with skin conditions compared to the general adult ICU popu-
lation highlights the importance of skin failure as a cause of
morbidity and mortality. Although conditions causing skin fail-
ure are rare, it is important to recognise that this is no less seri-
ous than any other organ system failure. As the broad aims of
ICU management are to maintain homeostasis, disruption of
skin function results in specific management problems. These
necessitate a multidisciplinary approach to management with
involvement of both intensivists and dermatologists, and
meticulous nursing care. The recent UK government proposal
to move dermatology services into the community [25] may
reduce the availability of a specialist dermatological opinion
Figure 2
Receiver operating characteristic curves for SCORTEN, the APACHE II score and the ICNARC model for admissions with toxic epidermal necrolysis  and related conditions (n = 145) Receiver operating characteristic curves for SCORTEN, the APACHE II score and the ICNARC model for admissions with toxic epidermal necrolysis 
and related conditions (n = 145).Available online http://ccforum.com/content/12/S1/S1
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and potentially compromise the care of this small number of
severely ill patients.
The size of the dataset available provides information on a
large number of patients; however it also has limitations in
terms of lacking detail. For example, we have no information on
the accuracy of the diagnoses, whether they were made by an
intensivist or a dermatologist, and whether diagnosis was con-
firmed by skin biopsy. Assigning a diagnosis to such patients
is further complicated by the various diagnostic criteria that
may have been used, for example in cases of SJS or TEN [5].
In order to calculate SCORTEN we assumed that patients
coded as TEN had involvement of greater than 10% of body
surface area and other patients did not. Patients with between
10 and 30% body surface area involvement may be consid-
ered 'overlap TEN/SJS' [6] and, if these were recorded solely
as SJS within our data, then the SCORTEN for these patients
would be incorrect. The available data do not provide any infor-
mation on the laboratory and physiological parameters before
admission to intensive care, and certain prognostic factors of
particular relevance to these patients, for example the percent-
age body surface area involvement, are not recorded in the
database.
The conditions included within the ICNARC coding method
[12], used to code the reasons for admission to ICU, are not
fully comprehensive. However, as this is a hierarchical system,
a method exists for coding any condition not specified in the
coding method by completing the hierarchical coding to as
much depth as possible and then recording the actual condi-
tion in the free text field. We identified 213 partially coded der-
matological admissions, of which 161 could be fully classified
using the information in the text field. For example, squamous
cell carcinomas are not included in the coding method but can
be recorded as 'surgical/dermatological/skin/tumour or malig-
nancy' with the final condition of 'squamous cell carcinoma' in
the free text field. It is, however, possible that some squamous
cell carcinomas were miscoded as melanomas or basal cell
carcinomas. Two squamous cell carcinomas recorded as
basal cell carcinomas were identified and reclassified
appropriately.
This study identifies patients with dermatological conditions
requiring admission to intensive care. However, it provides no
information on other patients with the same conditions, who
require inpatient care, but are not severe enough to need
intensive care or those who are not considered fit enough for
intensive care. For example an elderly patient with cellulitis
might die from sepsis, but not have been considered to be a
candidate for intensive care. Conversely, more severe cases
may have been referred directly to burns units, about which we
have no data. A number of patients with infective conditions,
TEN and related conditions, and scleroderma were transferred
to other ICUs. It is likely that some of these patients were
transferred to burns units where treatment outcomes may be
better for necrotising fasciitis and TEN [21,26].
While our study considers specifically those patients whose
primary or secondary reason for admission to intensive care
was a dermatological condition, there is also considerable
scope for patients with other conditions in intensive care to
require dermatological support [1,2]. The CMP dataset has
recently been revised to incorporate the new Critical Care
Minimum Data Set [27], which includes days of dermatologi-
cal support (defined as patients with major skin rashes, exfo-
liation or burns, use of multiple large trauma dressings, or use
of complex dressings). Once sufficient data are available, it will
be possible to examine all admissions to intensive care that
require such dermatological support.
Conclusion
This study highlights the importance of dermatological condi-
tions in the ICU. Skin conditions necessitating ICU admission
may be associated with severe physiological abnormalities,
and such patients have higher mortality and longer intensive
care stays than average for the UK adult ICU population. This
study provides further evidence for the importance of skin fail-
ure as a distinct entity, comparable to other major organ sys-
tem failures, with high mortality.
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